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Abstract
Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded unprecedented efficacy in B cell
malignancies, most remarkably in anti-CD19 CAR-T cells for B cell acute lymphoblastic leukemia (B-ALL) with up to a
90% complete remission rate. However, tumor antigen escape has emerged as a main challenge for the long-term
disease control of this promising immunotherapy in B cell malignancies. In addition, this success has encountered
significant hurdles in translation to solid tumors, and the safety of the on-target/off-tumor recognition of normal
tissues is one of the main reasons. In this mini-review, we characterize some of the mechanisms for antigen loss
relapse and new strategies to address this issue. In addition, we discuss some novel CAR designs that are being
considered to enhance the safety of CAR-T cell therapy in solid tumors.
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Background
Chimeric antigen receptor (CAR) is a modular fusion
protein comprising extracellular target binding domain
usually derived from the single-chain variable fragment
(scFv) of antibody, spacer domain, transmembrane
domain, and intracellular signaling domain containing
CD3z linked with zero or one or two costimulatory mol-
ecules such as CD28, CD137, and CD134 [1–3]. T cells
engineered to express CAR by gene transfer technology
are capable of specifically recognizing their target
antigen through the scFv binding domain, resulting in T
cell activation in a major histocompatibility complex
(MHC)-independent manner [4]. In the past several
years, clinical trials from several institutions to evaluate
CAR-modified T cell (CAR-T cell) therapy for B cell
malignancies including B cell acute lymphoblastic
leukemia (B-ALL), B cell non-Hodgkin’s lymphoma (B-
NHL), chronic lymphocytic leukemia (CLL), and Hodg-
kin’s lymphoma (HL) have demonstrated promising out-
comes by targeting CD19 [5–13], CD20 [14], or CD30
[15], where mostly compelling success has been achieved
in CD19-specific CAR-T cells for B-ALL with similar
high complete remission (CR) rates of 70~94% [5–8, 12].
This significant efficacy not only leads to an impending
paradigm shift in the treatment of B cell malignancies
but also results in a strong push toward expanding the
uses of CAR-T cell therapy for solid tumors. However,
the preliminary outcomes of clinical trials testing epider-
mal growth factor receptor (EGFR) [16], mesothelin
(MSLN) [17, 18], variant III of the epidermal growth fac-
tor receptor (EGFRvIII) [19], human epidermal growth
factor receptor-2 (HER2) [20, 21], carcinoembryonic
antigen (CEA) [22], and prostate-specific membrane
antigen (PSMA) [23] in solid tumors are less encour-
aging. Moreover, rapid death caused by the off-tumor
cross-reaction of CAR-T cells has been reported [20],
highlighting the important priority of enhancing CAR-T
cell therapy safety. Overall, there remain several power-
ful challenges to the broad application of CAR-T cell
therapy in the future: (1) antigen loss relapse, an emer-
ging threat to CAR-T cell therapy, mainly observed in
anti-CD19 CAR-T cells for B-ALL; (2) on-target/off-
tumor toxicity resulting from the recognition of healthy
tissues by CAR-T cells which can cause severe and even
life-threatening toxicities, especially in the setting of
solid tumors; (3) there is less efficacy in solid tumors,
mainly due to the hostile tumor microenvironment; (4)
difficulty of industrialization because of the personalized
autologous T cell manufacturing and widely “distributed”
approach. How to surmount these hurdles presents a
principal direction of CAR-T cell therapy development,
and a variety of strategies are now being investigated
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to address tumor antigen escape relapse and to enhance
the safety of CAR-T cells in solid tumors.
How to overcome antigen loss relapse in hematological
malignancies
Antigen escape rendering CAR-T cells ineffective against
tumor cells is an emerging threat to CAR-T cell therapy,
which has been mainly seen in the clinical trials involv-
ing CD19 in hematological malignancies. It appears to
be most common in B-ALL and has been observed in
approximately 14% of pediatric and adult responders
across institutions (Table 1) [5, 24–26]. It has also been
documented in CLL [27, 28] and primary mediastinal
large B cell lymphoma (PMLBCL) [29]. Indeed, it has
also been noted in patients who received blinatumomab
[30], a first-in-class bispecific T engager (BiTE) antibody
against CD19/CD3 [31, 32], which has also shown prom-
ising efficacy in B cell malignancies [33–35], implying
that this specific escape may result from the selective
pressure of CD19-directed T cell immunotherapy [36].
Moreover, tumor editing resulting from the selective
pressure exerted by CAR-T cell therapy also can be seen
when beyond CD19; we observed that a patient with
acute myeloid leukemia (AML) experienced selected
proliferation of leukemic cells with low saturation of
CD33 expression under the persistent stress of CD33-
Fig. 1 Future directions in CAR-T cell therapy. Overcoming antigen loss relapse and enhancing efficacy and safety present a principal direction of CAR-T
cell therapy optimization. “Off-the-shelf” CAR-T, a biologic that is pre-prepared in advance from one or more healthy unrelated donors, validated, and
cryopreserved and then can be shipped to patients worldwide, is deemed to be the ultimate product formulation. CAR chimeric antigen receptor, CAR-T
cell chimeric antigen receptor-modified T cell, B-ALL B cell acute lymphoblastic leukemia, B-NHL B cell non-Hodgkin’s lymphoma, CLL chronic lymphocytic
leukemia, HL Hodgkin’s lymphoma, MM multiple myeloma, EGFR epidermal growth factor receptor, MSLN mesothelin, HER2 human epidermal growth
factor receptor-2, EGFRvIII variant III of the epidermal growth factor receptor, PSMA prostate-specific membrane antigen, CEA carcinoembryonic antigen
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directed CAR-T cells [37]. Actually, antigen escape has
also been reported in the experimental study of solid
tumor, where targeting HER2 in a glioblastoma cell line
results in the emergence of HER2-null tumor cells that
maintain the expression of non-targeted, tumor-
associated antigens [38]. These findings suggest that
treatment of patients with specifically targeted therapies
such as CAR-T cell therapy always carry the risk of
tumor editing, highlighting that development of ap-
proaches to preventing and treating antigen loss escapes
would therefore represent a vertical advance in the field.
Given the extensive trials to date involving CD19, we
have gained a much better understanding regarding pos-
sible mechanism of these phenomena. Although all these
antigen escape relapses are characterized by the loss of
detectable CD19 on the surface of tumor cells, multiple
mechanisms are involved. One mechanism is that CD19
is still present but cannot be detected and recognized by
anti-CD19 CAR-T cells as its cell surface fragment con-
taining cognate epitope is absent because of deleterious
mutation and alternative splicing. Sotillo and colleagues
showed a CD19 isoform that skipped exon 2 (Δex2)
characterized by the loss of the cognate CD19 epitope
necessary for anti-CD19 CAR-T cells is strongly enriched
compared to prior anti-CD19 CAR-T cell treatment in
some patients with B-ALL who relapse after anti-CD19
CAR-T cell infusion. They estimated that this type of
antigen escape relapse would occur in 10 to 20% of
pediatric B-ALL treated with CD19-directed immuno-
therapy. Moreover, they found that this truncated
isoform was more stable than full-length CD19 and
partly rescued defects in cell proliferation and pre-B cell
receptor (pre-BCR) signaling associated with CD19 loss
[39]. Similar to that observed in B-ALL, a biopsy of renal
lesion from a patient with persistent renal involvement
by PMLBCL 2 months after anti-CD19 CAR-T cell infu-
sion indicated that activated anti-CD19 CAR-T cells
could infiltrate the tumor; however, the PMLBCL clone
is absent on surface CD19 but shows positive cytoplas-
mic expression [29]. These findings imply that it may
make sense to simultaneously evaluate the cytoplasmic
and membranous expression of CD19 by flow cytometry
and immunohistochemistry. Moreover, leukemic lineage
switch provides new insights into mechanisms of im-
mune escape from targeted immunotherapy [40]. Gard-
ner et al. reported on 2 of 7 patients with B-ALL
harboring rearrangement of the mixed lineage leukemia
(MLL) gene and achieving molecular CR after anti-
CD19 CAR-T cell infusion developing AML that was
clonally related to their B-ALL within 1 month after
anti-CD19 CAR-T cell infusion [41]. Both aforemen-
tioned phenomena can be recapitulated in a syngeneic
murine model where mice bearing E2a:PBX1 leukemia
are treated with murine anti-CD19 CAR-T cells [42].
Intriguingly, researchers demonstrated that earlier re-
lapses maintained pre-B phenotype with isolated CD19
loss, whereas later relapses involved multiple phenotypic
changes, including the loss of additional B cell markers.
Moreover, B cell-associated transcripts and an increase
in the expression of myeloid or T cell genes consistent
with lineage switching were also confirmed in later
relapses by unsupervised clustering of RNA sequencing,
implying that lineage switching results from reprogram-
ming rather than depletion of CD19 alone. Outgrowth
of preexisting rare CD19-negative malignant cells as a
consequence of immunoediting also can lead to B-ALL
cells escape anti-CD19 CAR-T cells killing, which is
described by Ruella et al. in research focusing on dual
CD19 and CD123 CAR-T cells [43]. They showed the
existence of rare CD19-negative CD123-positive cells at
baseline in the samples from patients with B-ALL. These
cells emerged after anti-CD19 CAR-T cell administra-
tion, which accounts for the CD19-negative relapse as
CD19-CD123+ blasts carried the disease-associated gen-
etic aberration and can lead to the reconstitution of the
original B-ALL phenotype when those cells are injected
into NOD/SCID/gamma (NSG)-chain-deficient mice.
On this basis, researchers developed a dual CAR-
expressing construct that combined CD19- and CD123-
mediated T cell activation and proved that this dual anti-
gen receptor can treat and prevent CD19-loss relapses in
a clinically relevant preclinical model of CD19-negative
leukemia escape. Similar phenomena have also been
shown in CLL, in which CD19-negative escape variants
were selected due to the treatment pressure exerted by
anti-CD19 CAR-T cells, which also resulted in the trans-
formation from CLL to plasmablastic lymphoma [28].
Novel strategies to offset tumor antigen loss relapse
are mainly geared toward generating T cells capable of
recognizing multiple antigens, in which dual-targeted
CAR-T cells have been actively investigated in preclinical
research and have two main patterns: modifying individ-
ual T cells with two distinct CAR molecules with two
different binding domains (known as dual-signaling
CAR) [38, 43] or with one CAR molecule containing
two different binding domains in tandem (termed Tan-
CAR) [44–46]. The prerequisite of the dual-targeted
CAR, either dual-signaling CAR or TanCAR, is that ei-
ther antigen input can trigger robust anti-tumor activity,
which ensures that there is always another antigen input
that can work well and control antigen loss relapse in
the setting of one antigen escape. The concept is simple
but is still a challenge in the context of limited choices
of clinically validated antigens and the constraint of suit-
able epitope selection in the setting of TanCAR [47].
Besides CD19, other pan-B cell markers such as CD20
[14] and CD22 [36] can be proposed as a target for dual-
targeted CAR in B cell malignancies as these antigen-
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directed CARs have been tested in humans and pre-
sented encouraging outcomes in early clinical trials.
Moreover, CD123 (also called IL-3 receptor α chain) is
also an ideal option for the target selection of dual-
targeted CAR [43, 48]. It is worth noting that enhanced
anti-tumor activity was demonstrated by dual-signaling
CAR or TanCAR compared to the unispecific CAR or
pooling unispecific CAR when both antigens are
expressed on the tumor cell surface [43, 45], highlighting
the safety concern. This design potentially increases the
risk of CRS and on-target/off-tumor recognition result-
ing from more significant CAR-T cell expansion in vivo
and cytokine release. In addition, whether the enhanced
immune pressure directly caused by the enhanced anti-
tumor activity can lead to loss of both antigens simultan-
eously because of tumor adaptation is another concern;
hence, targeting two antigens may not be enough, and
more studies are needed to determine the optimal antigen
combination for each cancer. Other tactics to achieve dual
recognition are pooling unispecific CAR-T cells; however,
coadministering two CAR-T cell populations may result in
the disproportionate expansion of one CAR-T cell sug-
gested by the observation that anti-CD19 CAR-T cells
have a significant growth advantage over CD20-specific
CAR-T cells when in a coculture system, leading to a net
decline in CD20-specific CAR-T cell count despite the
presence of CD20 antigen [44]. Furthermore, sequentially
infusing two groups of CAR-T cells [49] is also an alterna-
tive to avoid antigen escape and could circumvent the
disproportionate expansion as seen in pooling CAR-T
cells. However, it still is a combination of two groups of
CAR-T cells as pooling CAR-T cells, resulting in a rela-
tively long clinical time frame. Taken together, we would
prefer dual-targeted CAR-T cells, but much additional
work is needed to test and optimize this strategy before it
can be translated into humans. Right now, our group are
testing CD19/CD20 and CD19/CD22 dual-targeted CARs
for B cell malignancies in experimental studies. Moreover,
based on the lessons learned from the patient who
received anti-CD33 CAR-T cells [37], a CD33/CD123
dual-targeted CAR for AML has already been included in
our development pipeline.
On the other hand, selective targeting of cancer stem
cells (CSCs) rather than tumor cells for CAR-T cell ther-
apy may lead to better cancer treatment [50]. The reason
for that is CSCs retain extensive self-renewal and
tumorigenic potential, determining a tumor’s behavior,
including proliferation and progression [51]. CD133 is
an attractive therapeutic target for CAR-T cell therapy
when targeting CSCs [52]. We first tested a CD133-
directed CAR characterized by a shorted promoter in an
effort to minimize the risk of on-target/off-tumor recog-
nition in humans. A patient with cholangiocarcinoma,
who progressed after anti-EGFR CAR-T cell therapy, in
turn had another partial response with severe but can be
managed epidermal/endothelial toxicities may due to the
cross-reaction with CD133 expressed on normal epithe-
lium and vascular endothelium after treated with
CD133-directed CAR. These findings provide the proof-
of-concept evidence that anti-CD133 CAR confers
effective anti-tumor immunity which may contribute to
the long-term disease control, but the on-target/off-
tumor toxicity warrants further evaluation.
At the same time, some attention should be paid to the
endogenous immune system, albeit it cannot be effective
against tumor cells because of a lack of sufficient tumor-
specific T cells as well as suppression by the tumor im-
munosuppressive microenvironment. By increasing cyto-
kine production (e.g., IL-12) or the addition of immune
checkpoint inhibitors (e.g., anti-PD-1/PD-L1/CTLA-4
monoclonal antibodies), existing endogenous anti-tumor
immune cells can be rescued and may even induce epitope
spreading [53]. Epitope spreading is a process in which
antigenic epitopes distinct from and non-cross-reactive
with an inducing epitope become additional targets of an
ongoing immune response [54], which provides the
rationale for recruitment of endogenous immune cells to
recognize and eradicate a new relapsed tumor clone.
However, this hypothesis needs to be further verified in
upcoming clinical trials. The most thorough reconstitu-
tion of the immune system is allogeneic stem cell trans-
plantation (allo-SCT), in which a patient’s own
hematopoiesis is ablated through high-dose chemotherapy
or radiation. Regenerated normal hematopoiesis including
a new immune system can potentially recognize and des-
troy either type of tumor antigen escape relapse clone
[36]. Significantly, allo-SCT is performed at several institu-
tions for patients with B-ALL achieving CR after CAR-T
cell therapy, and it demonstrated reduced relapse rate
[25]. However, the Memorial Sloan Kettering Cancer Cen-
ter (MSKCC) group showed that among the 36 patients in
CR following CAR-T cell infusion, 6-month overall sur-
vival (OS) did not differ significantly between patients
who underwent allo-SCT (70%) and those who did not
(64%) [55]. We suggest pursuit of consolidative allo-SCT
for patients with B-ALL who achieve CR after CAR-T cell
therapy regardless of the persistence of CAR-T cells in
vivo, especially for patients who are thought to be at
higher risk of relapse.
How to enhance safety of CAR-T cells in solid tumors
Severe treatment-related toxicities mainly due to the on-
target/off-tumor recognition are another obstacle for
CAR-T cell therapy beyond hematological malignancies
[20]. How to abrogate the toxicity is crucial for this emer-
ging technology and has become a research hotspot. Strat-
egies for enhancing the safety of CAR-T cell therapy in
solid tumors fall into several categories (Table 2).
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Enhancing selectivity of CAR
Selecting safer antigen
CAR can only attack cells expressing targeted antigen;
hence, the most direct and effective means to surmount
off-tumor toxicities while not compromising efficacy is
by targeting truly tumor-specific antigen expressed only
on the tumor cells. However, the vast majority of CAR
targets have been tumor-associated antigens (TAAs) that
are overexpressed on tumor cells but also shared by nor-
mal “bystander” cells. Thus far, the only truly tumor-
specific antigen for CAR is EGFRvIII, which is strictly
confined to human cancer (most frequently observed
in glioblastoma) [56]. An early outcome of EGFRvIII-
specific CAR in 9 patients with EGFRvIII-positive
glioblastoma demonstrated that the infusion was well-
tolerated without off-tumor toxicities [19].
Of note, Posey et al. demonstrated that aberrantly
glycosylated antigen-Tn-MUC1 can also be proposed as
an ideal target for CAR-T cell therapy as selective recog-
nition of Tn- and STn-positive malignant tumors has
been achieved by T cells expressing 5E5 CAR, a newly
designed CAR containing scFv derived from antibody
5E5 specific for Tn and STn glycoepitopes [57]. More-
over, robust cytotoxicity of 5E5 CAR-T cells in murine
models of cancers as diverse as leukemia and pancreatic
cancer also have been observed. Although much remains
to be learned, these findings provide the proof-of-
concept evidence that aberrantly glycosylated antigens
can be proposed as a safer alternative than TAA for
CAR-T cell therapy.
If we turn our attention from membrane surface mole-
cules to the intracellular and/or secreted molecules, target
selection becomes rich in diversity. Cancer/testis antigens
(e.g., NY-ESO-1 and MAGE-A3) or differentiation
antigens (e.g., gp100 and MART1) represent the most
attractive targets for immunotherapy since these antigens
are expressed only by tumor cells and spermatogenic cells
from the testis or in a lineage-restricted manner [58].
However, antigens recognized by natural T cell receptor
(TCR) through peptides/MHC engagement are invisible
to conventional CAR as it can only recognize the mem-
brane surface antigen. One intriguing strategy for expand-
ing the antigenic repertoire to those antigens is using
TCR-like antibody, an antibody directed to peptide-MHC
(pMHC) complexes that can mimic the fine specificity of
tumor recognition by TCR while having higher affinity
than that of TCR [59]. T cells engineered to express the
CAR comprising scFv derived from TCR-like antibody
such as PR1/human leukocyte antigen (HLA-A2) or PR1/
HLA-A2 alpha-fetoprotein (AFP)/HLA-A*02:01, gp100/
HLA-A2 have been tested in vitro and in vivo [60–62],
and preliminary results demonstrate that this design is
feasible. However, several limitations are worth noting:
First, TCR-like CAR is HLA restricted; thus, the activation
of TCR-like CAR-T cells is not MHC independent. Sec-
ond, potential off-target/off-tumor toxicity results from
the cross-reactivity of these receptors with nonidentical
yet sequence-related HLA-I-binding peptides presented
by vital cells. Third, the extent of affinity constraints
for each peptide/MHC complexes is unclear; elegant
optimization is needed [63].
Combinatorial antigen targeting
Highly specific targets for CAR-T cell therapy are very
less; for a large majority of TAAs, one strategy for en-
hancing the specificity of CAR is combinatorial antigen
(mainly dual antigen) rather than one antigen targeting,




Selecting safer antigen Tumor-specific antigen Clinical trial [19]
Aberrantly glycosylated antigens Preclinical research [57]
TCR-like CAR Preclinical research [60–62]
Combinatorial antigen
targeting
Complementary signaling Preclinical research [64, 65]
SynNotch/CAR circulation Preclinical research [68]
iCAR Preclinical research [70]
Turning sensitivity of scFv Turning the affinity Preclinical research [74, 75]
Masked CAR Preclinical research [78]
Control CAR-T cell
activity
Limiting CAR expression Transient mRNA CAR Clinical trial [17, 18]
Switchable CAR-T cell Dimerizing small molecules Preclinical research [84, 85]
Tumor targeting antibody Preclinical research [86, 88, 90]
Suicide gene iCasp9 Clinical trial [92]
Antibody-mediated depletion Clinical trial [5, 9]
CAR chimeric antigen receptor, CAR-T cell chimeric antigen receptor-modified T cell, TCR T cell receptor, scFv single-chain variable fragment, SynNotch synthetic
Notch receptors, iCAR inhibitory chimeric antigen receptor, iCasp9 inducible caspase-9
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endowing CAR-T cells with the ability to discriminate
between target and off-target cells.
One design of combinatorial antigen targeting is sim-
ultaneously co-expressing two receptors with different
binding domain in the same T cell population. Of the
two receptors, one is a CAR containing CD3z signaling
domain alone and specific for one antigen, which can
provide the T cell activation signaling function. Another
receptor is a chimeric costimulatory receptor (CCR) that
recognizes another antigen, providing the costimulation
signaling function by CD28 and/or CD137. Theoretic-
ally, the T cells engineered with these complementary
dual receptors can only be fully activated in the context
of the presence of both antigens. In a proof-of-concept
experiment, Wilkie et al. showed that the T cells trans-
duced with a CAR specific for HER2 and a CCR specific
for MUC1 elicited enhanced T cell proliferation, which
is dependent on the engagement of HER2 and MUC1.
However, the cytolytic activity of these T cells is only
dependent on the engagement of HER2 irrespective of
MUC1, which was also observed [64], thus challenging
the implementation of these receptors. This non-double-
positive tumor-limiting T cell reactivity also resulted in
the failure of Kloss’ early experiments focusing on dual-
targeted T cells (CD19 and PSMA) [65]. To remedy this
failure, Kloss et al. constructed three anti-prostate stem
cell antigen (PSCA) CARs with different binding affinity
for PSCA by combination with the same CCR specific
for PSMA. The author tested these receptors in a human
xenograft tumor model in immunodeficient mice bear-
ing tumors expressing PSCA and/or PSMA. Signifi-
cantly, only the T cells expressing CAR with lower
binding affinity for PSCA demonstrated reactivity strictly
specific for PSCA and PSMA double-positive tumor
cells, providing an alternative option for increasing the
CAR specificity. However, practical questions remain to
be investigated, such as suitable TAA pairs uniquely
expressed on tumor cells with the desired range of affin-
ity selection [66].
Another design of combinatorial antigen targeting is
taking advantage of the synthetic Notch receptors (syn-
Notch), a new class of modular receptors comprising
extracellular recognition domain; the transmembrane
“core” domain; and the intracellular transcription
domain that can be cleaved and released by a transcrip-
tional activation domain translocating to the nucleus
and regulating transcription upon ligand engagement
[67]. By introducing the synNotch platform, Roybal et al.
constructed two combinatorial antigen recognition T cell
circuits [CD19 synNotch/MSLN CAR, green fluorescent
protein (GFP) synNotch/CD19 CAR] and demonstrated
that these receptors could conditionally express CARs
specific for a second antigen in the presence of the first
antigen-specific for the synNotch receptor [68].
Furthermore, in Jurkat T cells expressing CD19/MSLN,
the author observed that the effective half-time for
occurring CAR expression, T cell activation, and CAR
expression decay without synNotch stimulus were ~6,
~7, and ~8 h, respectively; this implies that these T cells
encounter the first antigen in one healthy cell, and soon
after the recognition of the second antigen in a different
healthy cell, they can only be transiently activated when
the CAR expression was downregulated because of the
absence of the first antigen. The author further tested
GFP and CD19 dual-targeted human primary CD4+ and
CD8+ T cells in a human xenograft two-tumor model
using K562 as a target; they observed the selective clear-
ance of CD19+GFP+ tumors rather than CD19+GFP−
“bystander” tumors (serving as surrogate “healthy
tissue”) in the same mice. Together, these findings not
only underscored the initial success of the synNotch/
CAR system in enhancing the specificity of CAR-T cell
therapy but also suggested that this system can poten-
tially expand to a wider range of tumors. However, the
potential toxicity toward normal human tissue, especially
in the event of a second antigen presence, is still a con-
cern as the abovementioned transient activation of T
cells. Moreover, CD19 and MSLN studied in this experi-
ment are actually not co-expressed in one tumor cell.
Together with immunogenicity concerns arising from
the use of multiple non-human transcriptional regulators
(Gal4, tTA), much additional work is required before
these types of T cell can be tested clinically [69].
Instead, if the dual antigens are simultaneously
expressed on healthy cells rather than on tumor cells,
the combination of inhibitory receptors (known as
iCAR) specific for the antigen present on normal but
not on tumor cells will protect the normal cells from a
CAR-T cell-mediated attack because of negative signal-
ing conferred by iCAR. Fedorov et al. pioneered an anti-
PSMA iCAR carrying intracellular tails of CTLA-4 or
PD-1 and tested whether these receptors have the ability
to block TCR- or CAR-driven T cell functionality in vitro
and in vivo [70]. This proof-of-concept experiment dem-
onstrated that the iCAR can inhibit the response medi-
ated by either TCR or CAR in an antigen-restricted
manner. Moreover, this inhibition mediated by iCAR is
in a temporary and reversible manner suggested by se-
quential T cell stimulation by target and off-target cell
experiments, which ensure that most of the T cells’ pre-
vious engagement of iCAR can retain the functionality,
albeit a small part of those T cells may be anergized over
time. In an in vitro coculture system mixing GFP+CD19
+ target AAPCs and mCherry+CD19+PSMA+ off-target
AAPCs at a 1:1 ratio, T cells expressing the PD-1 iCAR
and anti-CD19 CAR containing CD28 and CD3z signal-
ing domain showed preferential elimination of the target
cells while sparing the off-target cells. Together with the
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consistent results observed in NSG mice bearing a mix-
ture of NALM/6 and NALM/6-PSMA tumor cells indi-
cates those T cells can selectively protect off-target cells
without abrogating rejection of the target cells in vitro
and in vivo. This strategy is practically attractive for the
antigen broadly expressed in normal human tissue but
downregulated on tumor cells such as cell surface tumor
suppressor antigens and HLA molecules, which may be
targeted by iCAR to protect graft-versus-host disease
(GVHD) target tissues without impairing graft versus
tumor (GVT) in the setting of donor lymphocyte infu-
sion (DLI). However, for each targeted antigen, iCAR
needs elegant modification in scFv affinity, receptor ex-
pression level, and CAR/iCAR ratio as all these factors
are crucial for iCAR functionality.
Tuning the sensitivity of CAR
It is well recognized that there is a TCR affinity window
in which TCR with higher affinity can improve the rec-
ognition of the target antigen. However, beyond the TCR
affinity threshold for maximal T cell anti-tumor activity,
T cell activation cannot be improved or even be attenu-
ated by further enhancement; furthermore, the risk of
cross-reactivity with other self-derived pMHC complex
may increase [71, 72]. Similar phenomena were also
observed in the context of CAR, in which T cell activa-
tion is mediated by the antibody-derived scFv recogni-
tion of the target antigen [73]. Recently, two studies
further demonstrated that by turning the affinity of a
CAR, CAR-T cells could discriminate between tumor
cells and normal cells that express lower or normal
levels of the same antigen while retaining potent efficacy
in vivo [74, 75]. Turning sensitivity of CAR by scFv af-
finity provides an alternative approach to empowering
wider use of those targets overexpressed on tumor cells
for CAR-T cell therapy. However, the optimal affinity for
a scFv in the CAR format also depends on the location
of the target epitope, antigen density, length of spacer,
and other parameters such as the CAR expression level
and the nature of the signaling domain; thus, case-by-
case testing is necessary for an optimal CAR design [76].
Masked CAR
Protease-activated antibody (pro-antibody) is an anti-
body characterized by antigen-binding sites that are
masked until the antibody is activated by proteases com-
monly found in the tumor microenvironment [77]. Des-
noyers et al. designed an EGFR-targeting pro-antibody
(PB1) on the basis of cetuximab, and demonstrated that
PB1 was relatively inert in healthy non-human primates,
but could be locally activated and showed comparable
efficacy to cetuximab in two mouse models at clinically
accessible drug exposures [78]. Moreover, a higher pro-
tease activity rate was observed in a collection of human
tumor samples from lung and colon cancer patients,
suggesting that most of EGFR-positive human tumors
have the potential to activate PB1. Significantly, PB1 alle-
viates the dose-limiting cutaneous toxicity compared to
that caused by cetuximab in female cynomolgus mon-
keys, implying that the PB1 could be stably masked and
inactive in healthy tissues. Thus, these findings suggest
that using the scFv derived from those pro-antibody rep-
resents an attractive strategy for enhancing the selectiv-
ity of CAR toward targets shared with healthy tissues
[79]. However, the underlying mechanisms of activation
remains unclear, and more clinical models are needed to
further determine the safety before testing in clinical
trials.
Control CAR-T cell activity
Limiting CAR expression
Presently, the most common gene transfer strategies for
clinical work are viral techniques such as the retrovirus
or lentivirus that can result in permanent transgene
encoding CAR expression; however, these are disadvan-
tageous when severe toxicity related to CAR-T cell ther-
apy occurs [80]. One of the non-viral approaches,
electroporation of CAR mRNA characterized by transi-
ent CAR gene expression, is regarded as potentially safer
than the viral techniques when introducing a novel CAR
into patients [81]. Investigators at the University of
Pennsylvania (Upenn) first evaluated the MSLN-specific
mRNA CAR-T cells in patients with MSLN-expressing
solid tumors (NCT01355965) on the basis of the encour-
aging results of preclinical studies [81, 82] and demon-
strated the feasibility and safety of this novel strategy.
Together with the anti-tumor activity observed, this sup-
ported the development of the mRNA CAR-based strat-
egies for solid tumors [17, 18]. It is worth noting that
multiple infusions are necessary for mRNA CAR-T cells
due to the transient expression of transgene, enhancing
the risk of anaphylaxis as reported [18]. Taken together,
anti-MSLN CAR-T cells transduced with lentivirus were
designed and tested in the subsequent clinical trials
based on the safety profile shown in the MSLN-specific
mRNA CAR-T cells [83].
Switchable CAR-T
The switchable CAR is a novel design characterized by
incorporating switch molecules comprising dimerizing
small molecules or a tumor targeting antibody as a
bridge to link the two adjacent domains of the CAR
structure [84, 85] or tumor antigen and CAR-T cells
[86–89], by which the anti-tumor activity of the CAR-T
cells is strictly dependent on the receptor complex for-
mation in the presence of those switch molecules, open-
ing up opportunities to remotely control or terminate
the CAR-T cell response to avoid off-target toxicity that
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can occur immediately after T cell infusion. Wu et al.
showed a switchable CAR design, whereby separate
extracellular antigen-binding domain and intracellular
signaling component can be assembled through an
FKBP-FRB module only in the presence of heterodimer-
izing small molecules (rapamycin analog AP21967) con-
firmed by single-molecule imaging [85]. Wu et al. also
observed the efficient killing of target cells by switchable
CAR-T cells in vitro and in vivo, and this response was
regulated in a titratable manner. Similar outcomes were
observed in another switchable CAR by using a system
that is directly integrated into the hinge domain that
separates the scFv from the cell membrane [84]. Alterna-
tively, a group at the California Institute for Biomedical
Research developed antibody-based switches with site-
specific incorporation of fluorescein isothiocyanate
(FITC) or peptide neo-epitope (PNE) into a tumor
antigen-specific antibody, which can redirect the CAR-T
cells specific for corresponding FITC or PNE to tumor
cells expressing the same tumor antigens and forming a
switch-dependent immunological synapse [86, 88, 90].
They tested this system in B cell malignancies and breast
tumors by targeting CD19, CD22, and HER2 and dem-
onstrated that these switchable CAR-T cells have potent
antigen-specific and dose-dependent anti-tumor activity,
providing an attractive way to improve the safety of
CAR-T cell therapy in the clinic and suggesting that
these switchable CAR-T cells could be applicable to a
wide range of tumor antigens.
Suicide gene
Unlike the above-described that the CAR-T cell response
can be turned on again when the heterodimerizing small
molecules are present, the depletion of CAR-T cells by
incorporation of a suicide gene such as inducible
caspase-9 (iCasp9) enzyme is irreversible [91]. Di Stasi
et al. first tested the iCasp9-modified donor T cells in
haploidentical SCT recipients and showed that more
than 90% of the modified T cells were depleted within
30 min after administration of a single dose of dimeriz-
ing agent AP1903 among 4 patients developing GVHD
[92]. This rapid onset of action resulted in the fast
(within 24 h) and permanent abrogation of GVHD, al-
beit there remained a small number of residual iCasp9-
modified T cells. Currently, several clinical trials evaluat-
ing iCasp9-modified CAR-T cells are enrolling patients
(NCT02274584 and NCT02414269); however, these re-
sidual cell populations and the possibility of iCasp9
dimerization independent of dimerizing agent potentially
limit the widespread use of this strategy [93]. This select-
ive depletion can also be mediated by the clinically
approved therapeutic antibody when the transduced cells
are engineered to express the antibody targeted cell sur-
face antigen such as truncated EGFR (tEGFR) [94], a
human EGFR polypeptide retaining the intact cetuximab
binding site in extracellular domain III. Moreover,
tEGFR can serve as a cell surface marker for the identifi-
cation of the infused CAR-T cells in vivo and has been
used in clinical trials [5, 9]. Nonetheless, whether this
cell ablation through antibody-dependent cellular cyto-
toxicity can rapidly start in the event that severe toxicity
occurs in humans remains undetermined and needs to
be verified in forthcoming clinical trials.
Conclusions
CAR-T cells are the best-in-class example of genetic
engineering of T cells, bringing us spectacular opportun-
ities and hopefully entering the mainstream of cancer
therapy for B cell malignancies in the next 1–2 years.
But tumor antigen escape relapse resulting from select-
ive immune pressure of CAR-T cells highlights the
shortcomings of this novel modality. Moreover, a similar
surprise has not been elicited in the application of solid
tumors with less efficacy and on-target/off-tumor tox-
icity, suggesting that enhancing the efficacy and safety of
CAR-T cells should be considered as a starting point for
the novel CAR design. Encouragingly, the proof-of-
concept designs mentioned above to address these issues
have been tested in experimental studies, providing pre-
liminary evidence of feasibility and paving the road to
further optimization. Of these designs, targeting more
than one tumor antigen (i.e., dual-targeted CAR) should
take the front seat due to it is not only beneficial to
reducing or preventing the risk of antigen escape relapse
either in hematological malignancies or solid tumors but
also may alleviate the impact of antigenic heterogeneity
on therapeutic effect in solid tumors. However, the
prerequisite of the dual-targeted CAR for successfully
offsetting antigen escape relapse is that it can effectively
kill targets expressing either antigen, similarly to a
monospecific CAR. This places a significant restriction
on the implement in solid tumors as dual-targeted CAR
potentially enhances the risk of on-target/off-tumor
recognition compared to the unispecific CAR. In fact, as
discussed above, the concept of using more than one
target for CAR-T cell therapy in solid tumors mainly fo-
cuses on enhancing the specificity of CAR through the
design of combinatorial antigen targeting, by which T
cell only can be fully activated when the two target anti-
gens are present at the same time. Above all, dual-
targeted CAR is an optimal approach for overcoming
antigen escape relapse with manageable on-target/off-
tumor toxicity-B cell aplasia in B cell malignancies; how-
ever, it is still challenging to implement in solid tumors
because it is difficult to balance the therapeutic effect
and on-target/off-tumor toxicity. Combination tuning
the sensitivity of CAR by scFv affinity with suicide gene
may be a powerful strategy for broadening the
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application of dual-targeted CAR beyond hematological
malignancies. However, the eventual effects of these
novel designs still need to be determined in forthcoming
clinical trials.
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